Arrevus Receives FDA Qualified Infectious Disease Product (QIDP) Designation for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Jan 28, 2020 09:49 am
RALEIGH, N.C. -- 

Arrevus today announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation for ARV-1801 (sodium fusidate tablet) for the treatment of Cystic Fibrosis Pulmonary Exacerbations.

Pulmonary exacerbations (PEx) are episodes of acute worsening of pulmonary status that occur frequently in patients with cystic fibrosis and result in a sequential and permanent decline in lung function. There is currently no therapy specifically indicated to treat PEx in the United States. “We know that ARV-1801 is one of the very few oral antibiotics that has increased potency in low pH environments and also has anti-inflammatory activity, both of which are critical to any antibiotic targeting the lungs of CF patients experiencing an exacerbation.” – commented Dr. Carl N. Kraus, M.D., Founder and CEO of Arrevus.

Dr. Donald VanDevanter, Adjunct Professor at Case Western Reserve University School of Medicine, a member of the Cystic Fibrosis Foundation’s STOP (Standardized Treatment of Pulmonary Exacerbations) initiative, and an advisor to Arrevus, stated that “having the Cystic Fibrosis Respiratory Symptom Diary and Chronic Respiratory Infection Symptom Score (CFRSD-CRISS), a validated clinical endpoint specifically designed for PEx, brings real rigor to Arrevus’s efforts in an underserved area of CF management. The proposed superiority design to evaluate ARV-1801 for PEx treatment is indicative of a strong commitment to improve outcomes for people with CF and their families, and I’m excited to support their efforts.”

About ARV-1801
ARV-1801 (sodium fusidate) is the only member of the fusidane class of antibiotics that is available globally and is considered a New Molecular Entity in the United States. Arrevus is planning to initiate a phase 2 study to examine ARV-1801 in the treatment of pulmonary exacerbations in patients with cystic fibrosis. Sodium fusidate is included in multiple treatment guidelines outside of the U.S. for bacterial decolonization in cystic fibrosis patients.

About Arrevus
Arrevus develops novel therapeutics for orphan diseases that are associated with high treatment failure rates, few therapeutic options and serious outcomes.

Arrevus is headquartered in Raleigh, N.C. For more information about Arrevus Inc., visit www.arrevus.com or email [email protected].

Denise Watts, [email protected]

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).